Diagnostic and therapeutic imaging for cancer: Therapeutic considerations and future directions

Journal of Surgical Oncology

Volumn 103, Issue 6, 2011, Pages 587-601

  Roach III, MacK ^a   Alberini, Jean Louis ^b   Pecking, Alain Paul ^b   Testori, Alessandro ^c   Verrecchia, Francesco ^c   Soteldo, Javier ^c   Ganswindt, Ute ^d   Joyal, John L ^e   Babich, John W ^e   Witte, Russell S ^f   Unger, Evan ^f   Gottlieb, Ronald ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUT CURIE   (France)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d UNIVERSITY OF MUNICH   (Germany)

^e A Subsidiary of Lantheus Holdings   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

Author keywords

lymph node imaging; PET CT; sentinel node imaging; SPECT CT; ultrasound imaging

Indexed keywords

PROSTATE SPECIFIC MEMBRANE ANTIGEN;

CAMERA; CANCER CELL; CANCER DIAGNOSIS; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; MELANOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTOACOUSTIC SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SENTINEL LYMPH NODE BIOPSY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR BLOOD FLOW; ULTRASOUND;

DIAGNOSTIC IMAGING; HUMANS; MICROSCOPY, ACOUSTIC; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; SENTINEL LYMPH NODE BIOPSY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 79953841975     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21805     Document Type: Review

References (152)

1. Folkman J,: Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
2. Weidner N, Semple JP, Welch WR, et al.: Tumor angiogenesis and metastasis-Correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
3. Zetter BR,: Angiogenesis and tumor metastasis. Annu Rev Med 1998; 49: 407-424. (Pubitemid 28197463)
4. Brooks PC, Clark RA, Cheresh DA,: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264: 569-571.
5. Ellegala DB, Leong-Poi H, Carpenter JE, et al.: Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation 2003; 108: 336-341. (Pubitemid 36899026)
6. Choi JH, Ahn MJ, Rhim HC, et al.: Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma. Cancer Res Treat 2005; 37: 290-293.
7. Friedlander M, Brooks PC, Shaffer RW, et al.: Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995; 270: 1500-1502. (Pubitemid 3005294)
8. Weidner N, Carroll PR, Flax J, et al.: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401-409. (Pubitemid 24058195)
9. Angeletti CA, Lucchi M, Fontanini G, et al.: Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (stage IIIA-N2). Impact of adjuvant therapies in a subset of patients at high risk of recurrence. Cancer 1996; 78: 409-415. (Pubitemid 26250524)
10. Millauer B, Shawver LK, Plate KH, et al.: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994; 367: 576-579.
11. Leggett DA, Kelley BB, Bunce IH, et al.: Colorectal cancer: Diagnostic potential of CT measurements of hepatic perfusion and implications for contrast enhancement protocols. Radiology 1997; 205: 716-720. (Pubitemid 27516706)
12. Sahani DV, Kalva SP, Hamberg LM, et al.: Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: Initial observations. Radiology 2005; 234: 785-792. (Pubitemid 40250822)
13. Ash L, Teknos TN, Gandhi D, et al.: Head and neck squamous cell carcinoma: CT perfusion can help noninvasively predict intratumoral microvessel density. Radiology 2009; 251: 422-428.
14. Thukral A, Thomasson DM, Chow CK, et al.: Inflammatory breast cancer: Dynamic contrast-enhanced MR in patients receiving bevacizumab-Initial experience. Radiology 2007; 244: 727-735. (Pubitemid 47292083)
15. Mayr NA, Yuh WT, Magnotta VA, et al.: Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: A new noninvasive predictive assay. Int J Radiat Oncol Biol Phys 1996; 36: 623-633. (Pubitemid 27000034)
16. Dzik-Jurasz A, Domenig C, George M, et al.: Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002; 360: 307-308. (Pubitemid 34874724)
17. Kim S, Loevner L, Quon H, et al.: Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res 2009; 15: 986-994.
18. Deng J, Miller FH, Salem R, et al.: Multishot diffusion-weighted PROPELLER magnetic resonance imaging of the abdomen. Invest Radiol 2006; 41: 769-775. (Pubitemid 44401304)
19. Shukla-Dave A, Poptani H, Loevner LA, et al.: Prediction of treatment response of head and neck cancers with P-31 MR spectroscopy from pretreatment relative phosphomonoester levels. Acad Radiol 2002; 9: 688-694. (Pubitemid 34568804)
20. Mukherji SK, Schiro S, Castillo M, et al.: Proton MR spectroscopy of squamous cell carcinoma of the extracranial head and neck: In vitro and in vivo studies. AJNR Am J Neuroradiol 1997; 18: 1057-1072. (Pubitemid 30412127)
21. Dawson D, Vincent MA, Barrett EJ, et al.: Vascular recruitment in skeletal muscle during exercise and hyperinsulinemia assessed by contrast ultrasound. Am J Physiol Endocrinol Metab 2002; 282: E714-E720. (Pubitemid 34654790)
22. Wei K, Jayaweera AR, Firoozan S, et al.: Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation 1998; 97: 473-483. (Pubitemid 28090220)
23. Burns PN, Wilson SR, Simpson DH,: Pulse inversion imaging of liver blood flow: Improved method for characterizing focal masses with microbubble contrast. Invest Radiol 2000; 35: 58-71. (Pubitemid 30033608)
24. Iordanescu I, Becker C, Zetter B, et al.: Tumor vascularity: Evaluation in a murine model with contrast-enhanced color Doppler US effect of angiogenesis inhibitors. Radiology 2002; 222: 460-467. (Pubitemid 34106120)
25. Forsberg F, Dicker AP, Thakur ML, et al.: Comparing contrast-enhanced ultrasound to immunohistochemical markers of angiogenesis in a human melanoma xenograft model: Preliminary results. Ultrasound Med Biol 2002; 28: 445-451. (Pubitemid 34603764)
26. Alberini JL, Giraudet AL, Champion L, et al.: Single photon emission tomography/computed tomography and positron emission tomography/computed tomography (SPET/PET/CT) to image cancer. J Surg Oncol.
27. Weber WA,: Positron emission tomography as an imaging biomarker. J Clin Oncol 2006; 24: 3282-3292. (Pubitemid 46622068)
28. Su H, Bodenstein C, Dumont RA, et al.: Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 2006; 12: 5659-5667. (Pubitemid 44629592)
29. Weber WA, Figlin R,: Monitoring cancer treatment with PET/CT: Does it make a difference? J Nucl Med 2007; 48: 36S-44S. (Pubitemid 47604941)
30. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001; 61: 1781-1785. (Pubitemid 32691983)
31. Vajkoczy P, Schilling L, Ullrich A, et al.: Characterization of angiogenesis and microcirculation of high-grade glioma: An intravital multifluorescence microscopic approach in the athymic nude mouse. J Cereb Blood Flow Metab 1998; 18: 510-520. (Pubitemid 28213535)
32. Vajkoczy P, Ullrich A, Menger MD,: Intravital fluorescence videomicroscopy to study tumor angiogenesis and microcirculation. Neoplasia 2000; 2: 53-61. (Pubitemid 30123180)
33. Xu Z, Li C, Wang LV,: Photoacoustic tomography of water in phantoms and tissue. J Biomed Opt 2010; 15: 036019.
34. Ophir J, Cespedes I, Ponnekanti H, et al.: Elastography: A quantitative method for imaging the elasticity of biological tissues. Ultrason Imaging 1991; 13: 111-134.
35. Kaluzynski K, Chen X, Emelianov SY, et al.: Strain rate imaging using two-dimensional speckle tracking. IEEE Trans Ultrason Ferroelectr Freq Control 2001; 48: 1111-1123. (Pubitemid 32742822)
36. Itoh A, Ueno E, Tohno E, et al.: Breast disease: Clinical application of US elastography for diagnosis. Radiology 2006; 239: 341-350.
37. Pellot-Barakat C, Frouin F, Insana MF, et al.: Ultrasound elastography based on multiscale estimations of regularized displacement fields. IEEE Trans Med Imaging 2004; 23: 153-163.
38. Barr RG,: Real-time ultrasound elasticity of the breast: Initial clinical results. Ultrasound Q 2010; 26: 61-66.
39. Fung YC,: Mechanical properties of living tissues biomechanics. New York: Springer; 1993.
40. Samani A, Zubovits J, Plewes D,: Elastic moduli of normal and pathological human breast tissues: An inversion-technique-based investigation of 169 samples. Phys Med Biol 2007; 52: 1565-1576. (Pubitemid 46646367)
41. Insana M, Oelze M,: Advanced ultrasonic imaging techniques for breast cancer research. In:, Suri JS, Rangayyan R, Laxminarayan S, editors. Emerging technologies in breast imaging and mammography, Valencia: American Scientific Publishers; 2006. ISBN: 1-58883-090-x.
42. Hall TJ,: AAPM/RSNA physics tutorial for residents: Topics in US: Beyond the basics: Elasticity imaging with US. Radiographics 2003; 23: 1657-1671. (Pubitemid 37487540)
43. Wojcinski S, Farrokh A, Weber S, et al.: Multicenter study of ultrasound real-time tissue elastography in 779 cases for the assessment of breast lesions: Improved diagnostic performance by combining the BI-RADS(R)-US classification system with sonoelastography. Ultraschall Med 2010; 31: 484-491. [Epub 2010 Apr 20].
44. Miyanaga N, Akaza H, Yamakawa M, et al.: Tissue elasticity imaging for diagnosis of prostate cancer: A preliminary report. Int J Urol 2006; 13: 1514-1518. (Pubitemid 44786339)
45. Sumura M, Shigeno K, Hyuga T, et al.: Initial evaluation of prostate cancer with real-time elastography based on step-section pathologic analysis after radical prostatectomy: A preliminary study. Int J Urol 2007; 14: 811-816. (Pubitemid 47313273)
46. Ginat DT, Destounis SV, Barr RG, et al.: US elastography of breast and prostate lesions. Radiographics 2009; 29: 2007-2016.
47. Evaluation, Ultrasound Elasticity/Tissue Strain-Hardening Imaging for Prostate Cancer Patients Undergoing Radical Prostatectomy. Ongoing clinical trial (2009). M.D. Anderson Cancer Center. Houston, M.D. Anderson Cancer Center, 2009.
48. Ermilov SA, Khamapirad T, Conjusteau A, et al.: Laser optoacoustic imaging system for detection of breast cancer. J Biomed Opt 2009; 14: 024007.
49. Manohar S, Vaartjes SE, van Hespen JC, et al.: Initial results of in vivo non-invasive cancer imaging in the human breast using near-infrared photoacoustics. Opt Express 2007; 15: 12277-12285. (Pubitemid 47460091)
50. Wang X, Pang Y, Ku G, et al.: Noninvasive laser-induced photoacoustic tomography for structural and functional in vivo imaging of the brain. Nat Biotechnol 2003; 21: 803-806. (Pubitemid 36791400)
51. Zhang HF, Maslow K, Sivaramakrishnan M, et al.: Imaging of hemoglobin oxygen saturation variations in single vessels in vivo using photoacoustic microscopy. Appl Phys Lett 2007; 90: 053901.
52. Lungu GF, Li ML, Xie X, et al.: In vivo imaging and characterization of hypoxia-induced neovascularization and tumor invasion. Int J Oncol 2007; 30: 45-54.
53. Montilla L, Olafsson R, Witte RS,: Real-time pulse echo and photoacoustic imaging using an ultrasound array and in-line reflective illumination. Proc. SPIE 2010; 75643C-10.
54. Yao J, Maslov K, Hu S, et al.: Evans blue dye-enhanced capillary-resolution photoacoustic microscopy in vivo. J Biomed Opt 2009; 14: 054049.
55. Song KH, Kim C, Cobley CM, et al.: Near-infrared gold nanocages as a new class of tracers for photoacoustic sentinel lymph node mapping on a rat model. Nano Lett 2009; 9: 183-188.
56. Kim C, Song KH, Gao F, et al.: Sentinel lymph nodes and lymphatic vessels: Noninvasive dual-modality in vivo mapping by using indocyanine green in rats-Volumetric spectroscopic photoacoustic imaging and planar fluorescence imaging. Radiology 2010; 255: 442-450.
57. Li PC, Wang CR, Shieh DB, et al.: In vivo photoacoustic molecular imaging with simultaneous multiple selective targeting using antibody-conjugated gold nanorods. Opt Express 2008; 16: 18605-18615.
58. Goldberg BB, Merton DA, Liu JB, et al.: Contrast-enhanced sonographic imaging of lymphatic channels and sentinel lymph nodes. J Ultrasound Med 2005; 24: 953-965. (Pubitemid 40885182)
59. Liu C, Liang P, Wang Y, et al.: Assessment of hepatic VX(2) tumors with combined percutaneous transhepatic lymphosonography and contrast-enhanced ultrasonographic imaging. World J Gastroenterol 2008; 14: 3908-3913.
60. Galanzha EI, Shashkov EV, Tuchin VV, et al.: In vivo multispectral, multiparameter, photoacoustic lymph flow cytometry with natural cell focusing, label-free detection and multicolor nanoparticle probes. Cytometry A 2008; 73: 884-894.
61. Galanzha EI, Kokoska MS, Shashkov EV, et al.: In vivo fiber-based multicolor photoacoustic detection and photothermal purging of metastasis in sentinel lymph nodes targeted by nanoparticles. J Biophotonics 2009; 2: 528-539.
62. Galanzha EI, Kim JW, Zharov VP,: Nanotechnology-based molecular photoacoustic and photothermal flow cytometry platform for in-vivo detection and killing of circulating cancer stem cells. J Biophotonics 2009; 2: 725-735.
63. De la Zerda A, Zavaleta C, Keren S, et al.: Carbon nanotubes as photoacoustic molecular imaging agents in living mice. Nat Nanotechnol 2008; 3: 557-562.
64. Li PC, Wei CW, Liao CK, et al.: Photoacoustic imaging of multiple targets using gold nanorods. IEEE Trans Ultrason Ferroelectr Freq Control 2007; 54: 1642-1647.
65. Stantz KM, Liu B, Cao M, et al.: Photoacoustic spectroscopic imaging of intra-tumor heterogeneity and molecular identification. Proc. SPIE 2006; 6086: 608605.
66. Emelianov SY, Li PC, O'Donnell M,: Photoacoustics for molecular imaging and therapy. Phys Today 2009; 62: 34-39.
67. Mariani G, Bruselli L, Kuwert T, et al.: A review on the clinical uses of SPECT/CT. Eur J Nucl Med Mol Imaging 2010; 37: 1959-1985.
68. O'Connor MK, Kemp BJ,: Single-photon emission computed tomography/computed tomography: Basic instrumentation and innovations. Semin Nucl Med 2006; 36: 258-266. (Pubitemid 44300996)
69. von Schulthess GK,: Integrated modality imaging with PET-CT and SPECT-CT: CT issues. Eur Radiol 2005; 15: D121-D126.
70. Hasegawa BH, Wong KH, Iwata K, et al.: Dual-modality imaging of cancer with SPECT/CT. Technol Cancer Res Treat 2002; 1: 449-458. (Pubitemid 36548521)
71. Krausz Y, Keidar Z, Kogan I, et al.: SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf) 2003; 59: 565-573. (Pubitemid 37357615)
72. Schillaci O, Danieli R, Manni C, et al.: Is SPECT/CT with a hybrid camera useful to improve scintigraphic imaging interpretation? Nucl Med Commun 2004; 25: 705-710. (Pubitemid 38901688)
73. Schillaci O, Simonetti G,: Fusion imaging in nuclear medicine- Applications of dual-modality systems in oncology. Cancer Biother Radiopharm 2004; 19: 1-10. (Pubitemid 38352280)
74. Castaldi P, Rufini V, Treglia G, et al.: Impact of 111In-DTPA-octreotide SPECT/CT fusion images in the management of neuroendocrine tumours. Radiol Med 2008; 113: 1056-1067.
75. Even-Sapir E, Keidar Z, Bar-Shalom R,: Hybrid imaging (SPECT/CT and PET/CT)-Improving the diagnostic accuracy of functional/metabolic and anatomic imaging. Semin Nucl Med 2009; 39: 264-275.
76. Patton JA, Townsend DW, Hutton BF,: Hybrid imaging technology: From dreams and vision to clinical devices. Semin Nucl Med 2009; 39: 247-263.
77. Spanu A, Solinas ME, Chessa F, et al.: 131I SPECT/CT in the follow-up of differentiated thyroid carcinoma: Incremental value versus planar imaging. J Nucl Med 2009; 50: 184-190.
78. Chowdhury FU, Scarsbrook AF,: The role of hybrid SPECT-CT in oncology: Current and emerging clinical applications. Clin Radiol 2008; 63: 241-251.
79. Wong KK, Zarzhevsky N, Cahill JM, et al.: Hybrid SPECT-CT and PET-CT imaging of differentiated thyroid carcinoma. Br J Radiol 2009; 82: 860-876.
80. Ingui CJ, Shah NP, Oates ME,: Endocrine neoplasm scintigraphy: Added value of fusing SPECT/CT images compared with traditional side-by-side analysis. Clin Nucl Med 2006; 31: 665-672. (Pubitemid 44624550)
81. Patton JA, Turkington TG,: SPECT/CT physical principles and attenuation correction. J Nucl Med Technol 2008; 36: 1-10. (Pubitemid 351520586)
82. Tharp K, Israel O, Hausmann J, et al.: Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur J Nucl Med Mol Imaging 2004; 31: 1435-1442. (Pubitemid 39361941)
83. von Schulthess GK,: Positron emission tomography versus positron emission tomography/computed tomography: From "unclear" to "new-clear" medicine. Mol Imaging Biol 2004; 6: 183-187.
84. Berthelsen AK, Holm S, Loft A, et al.: PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging 2005; 32: 1167-1175. (Pubitemid 41355943)
85. Buck AK, Nekolla S, Ziegler S, et al.: Spect/Ct. J Nucl Med 2008; 49: 1305-1319.
86. Bybel B, Brunken RC, DiFilippo FP, et al.: SPECT/CT imaging: Clinical utility of an emerging technology. Radiographics 2008; 28: 1097-1113.
87. Pecking AP, Wartski M, Cluzan RV, et al.: SPECT-CT fusion imaging radionuclide lymphoscintigraphy: Potential for limb lymphedema assessment and sentinel node detection in breast cancer. Cancer Treat Res 2007; 135: 79-84.
88. Patel CN, Chowdhury FU, Scarsbrook AF,: Hybrid SPECT/CT: The end of "unclear" medicine. Postgrad Med J 2009; 85: 606-613.
89. Bockisch A, Freudenberg LS, Schmidt D, et al.: Hybrid imaging by SPECT/CT and PET/CT: Proven outcomes in cancer imaging. Semin Nucl Med 2009; 39: 276-289.
90. Maurer AH,: Combined imaging modalities: PET/CT and SPECT/CT. Health Phys 2008; 95: 571-576.
91. Delbeke D, Schoder H, Martin WH, et al.: Hybrid imaging (SPECT/CT and PET/CT): Improving therapeutic decisions. Semin Nucl Med 2009; 39: 308-340.
92. Dragan R, Nebojsa M, Dejan S, et al.: Clinical application of sentinel lymph node biopsy for staging, treatment and prognosis of colon and gastric cancer. Hepatogastroenterology 2009; 56: 1606-1611.
93. Thompson JF, Uren RF,: Lymphatic mapping in management of patients with primary cutaneous melanoma. Lancet Oncol 2005; 6: 877-885. (Pubitemid 41614800)
94. Rossi CR, De Salvo GL, Trifiro G, et al.: The impact of lymphoscintigraphy technique on the outcome of sentinel node biopsy in 1,313 patients with cutaneous melanoma: An Italian Multicentric Study (SOLISM-IMI). J Nucl Med 2006; 47: 234-241. (Pubitemid 46780887)
95. Kapteijn BA, Nieweg OE, Liem I, et al.: Localizing the sentinel node in cutaneous melanoma: Gamma probe detection versus blue dye. Ann Surg Oncol 1997; 4: 156-160. (Pubitemid 127729059)
96. Vidal-Sicart S, Roé N, Paredes P, et al.: Comparison between a Gamma Probe and a Portable Gamma Camera for SLN Intraoperative Detection: Technical Features, Phantom Studies and First Image Guided SLN Resection, 2006; Rome.
97. Fernández MM, Benllocha JM, Cerdá J, et al.: A flat-panel-based mini gamma camera for lymph nodes studies. Nucl Instrum Methods Phys Res 2004; 527: 92-96.
98. Eggermont AM, Voit C,: Management of melanoma: A European perspective. Surg Oncol Clin N Am 2008; 17: 635-648, x. (Pubitemid 351699254)
99. Hocevar M, Bracko M, Pogacnik A, et al.: The role of preoperative ultrasonography in reducing the number of sentinel lymph node procedures in melanoma. Melanoma Res 2004; 14: 533-536. (Pubitemid 40221146)
100. Voit C, Kron M, Schafer G, et al.: Ultrasound-guided fine needle aspiration cytology prior to sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol 2006; 13: 1682-1689. (Pubitemid 44951477)
101. Landercasper J, Gundersen SB, Jr., Gundersen AL, et al.: Needle localization and biopsy of nonpalpable lesions of the breast. Surg Gynecol Obstet 1987; 164: 399-403. (Pubitemid 17079658)
102. Silverstein MJ, Gamagami P, Rosser RJ, et al.: Hooked-wire-directed breast biopsy and overpenetrated mammography. Cancer 1987; 59: 715-722. (Pubitemid 17018746)
103. Gennari R, Galimberti V, De Cicco C, et al.: Use of technetium-99m- labeled colloid albumin for preoperative and intraoperative localization of nonpalpable breast lesions. J Am Coll Surg 2000; 190: 692-698; discussion 698-699.
104. Paganelli G, Luini A, Veronesi U,: Radioguided occult lesion localization (ROLL) in breast cancer: Maximizing efficacy, minimizing mutilation. Ann Oncol 2002; 13: 1839-1840. (Pubitemid 36040771)
105. Paganelli G, Veronesi U,: Innovation in early breast cancer surgery: Radio-guided occult lesion localization and sentinel node biopsy. Nucl Med Commun 2002; 23: 625-627. (Pubitemid 34748001)
106. De Cicco C, Trifiro G, Intra M, et al.: Optimised nuclear medicine method for tumour marking and sentinel node detection in occult primary breast lesions. Eur J Nucl Med Mol Imaging 2004; 31: 349-354. (Pubitemid 38314078)
107. van Esser S, Hobbelink MG, Peeters PH, et al.: The efficacy of 'radio guided occult lesion localization' (ROLL) versus 'wire-guided localization' (WGL) in breast conserving surgery for non-palpable breast cancer: A randomized clinical trial-Roll study. BMC Surg 2008; 8: 9.
108. Testori A, Rastrelli M, De Fiori E, et al.: Radio-guided ultrasound lymph node localization: Feasibility of a new technique for localizing and excising nonpalpable lymph nodes ultrasound suspicious for melanoma metastases. Melanoma Res 2010; 20: 197-202.
109. Krag D, Weaver D, Ashikaga T, et al.: The sentinel node in breast cancer-A multicenter validation study. N Engl J Med 1998; 339: 941-946. (Pubitemid 28455095)
110. Morton DL, Wen DR, Wong JH, et al.: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-399.
111. Horenblas S, Jansen L, Meinhardt W, et al.: Detection of occult metastasis in squamous cell carcinoma of the penis using a dynamic sentinel node procedure. J Urol 2000; 163: 100-104.
112. Holl G, Dorn R, Wengenmair H, et al.: Validation of sentinel lymph node dissection in prostate cancer: Experience in more than 2,000 patients. Eur J Nucl Med Mol Imaging 2009; 36: 1377-1382.
113. Veronesi U, Paganelli G, Viale G, et al.: A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349: 546-553. (Pubitemid 36951366)
114. Wawroschek F, Vogt H, Wengenmair H, et al.: Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases. Urol Int 2003; 70: 303-310. (Pubitemid 36566262)
115. Weckermann D, Dorn R, Trefz M, et al.: Sentinel lymph node dissection for prostate cancer: Experience with more than 1,000 patients. J Urol 2007; 177: 916-920. (Pubitemid 46216337)
116. Vermeeren L, Valdes Olmos RA, Meinhardt W, et al.: Value of SPECT/CT for detection and anatomic localization of sentinel lymph nodes before laparoscopic sentinel node lymphadenectomy in prostate carcinoma. J Nucl Med 2009; 50: 865-870.
117. Bolla M, Collette L, Blank L, et al.: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002; 360: 103-106.
118. Pommier P, Chabaud S, Lagrange JL, et al.: Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 2007; 25: 5366-5373. (Pubitemid 350232211)
119. Roach M III, DeSilvio M, Lawton C, et al.: Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003; 21: 1904-1911. (Pubitemid 46606377)
120. Shariat SF, Kattan MW, Erdamar S, et al.: Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein. J Clin Oncol 2003; 21: 1223-1231. (Pubitemid 46606397)
121. Pagliarulo V, Hawes D, Brands FH, et al.: Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol 2006; 24: 2735-2742. (Pubitemid 46630570)
122. Ferrari AC, Stone NN, Kurek R, et al.: Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. J Clin Oncol 2006; 24: 3081-3088. (Pubitemid 46638944)
123. Weckermann D, Dorn R, Holl G, et al.: Limitations of radioguided surgery in high-risk prostate cancer. Eur Urol 2007; 51: 1549-1556; discussion 1556-1558.
124. Roach M, Wallner K, Hsu I-CJ, et al.: Cancer of the prostate. In:, Hoppe RT, Phillips TL, Roach M III, editors. Leibel and Phillips Textbook of Radiation Oncology. Chapter 45, 3rd edition. Elsevier Saunders 2010; 925-986.
125. Lawton CA, DeSilvio M, Roach M III, et al.: An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007; 69: 646-655. (Pubitemid 47418390)
126. Roach M III, DeSilvio M, Valicenti R, et al.: Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 2006; 66: 647-653. (Pubitemid 44436716)
127. Ganswindt U, Paulsen F, Corvin S, et al.: Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition. BMC Cancer 2005; 5: 91.
128. Martinez-Monge R, Fernandes PS, Gupta N, et al.: Cross-sectional nodal atlas: A tool for the definition of clinical target volumes in three-dimensional radiation therapy planning. Radiology 1999; 211: 815-828. (Pubitemid 29249485)
129. Heidenreich A, Varga Z, Von Knobloch R,: Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: High incidence of lymph node metastasis. J Urol 2002; 167: 1681-1686. (Pubitemid 34240702)
130. Bader P, Burkhard FC, Markwalder R, et al.: Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 2002; 168: 514-518; discussion 518. (Pubitemid 34793284)
131. Burkhard FC, Schumacher M, Thalmann GN, et al.: Is pelvic lymphadenectomy really necessary in patients with a serum prostate-specific antigen level of <10ng/ml undergoing radical prostatectomy for prostate cancer? BJU Int 2005; 95: 275-278. (Pubitemid 40283106)
132. Ganswindt U, Paulsen F, Corvin S, et al.: Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique. Int J Radiat Oncol Biol Phys 2007; 67: 347-355. (Pubitemid 46108338)
133. Ganswindt U, Schilling D, Muller AC, et al.: Distribution of prostate sentinel nodes: A SPECT-derived Anatomic Atlas. Int J Radiat Oncol Biol Phys 2010 Aug 24. [Epub ahead of print].
134. Lapidus RG, Tiffany CW, Isaacs JT, et al.: Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate 2000; 45: 350-354.
135. Pinto JT, Suffoletto BP, Berzin TM, et al.: Prostate-specific membrane antigen: A novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996; 2: 1445-1451. (Pubitemid 126447436)
136. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al.: In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 2000; 60: 5237-5243.
137. Ross JS, Sheehan CE, Fisher HA, et al.: Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003; 9: 6357-6362. (Pubitemid 38031820)
138. Tasch J, Gong M, Sadelain M, et al.: A unique folate hydrolase, prostate-specific membrane antigen (PSMA): A target for immunotherapy? Crit Rev Immunol 2001; 21: 249-261. (Pubitemid 32959364)
139. Schulke N, Varlamova OA, Donovan GP, et al.: The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci USA 2003; 100: 12590-12595. (Pubitemid 37339943)
140. Chang SS, Reuter VE, Heston WD, et al.: Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999; 59: 3192-3198. (Pubitemid 29316022)
141. Stoermer D, Liu Q, Hall MR, et al.: Synthesis and biological evaluation of hydroxamate-Based inhibitors of glutamate carboxypeptidase II. Bioorg Med Chem Lett 2003; 13: 2097-2100. (Pubitemid 36694282)
142. Speno HS, Luthi-Carter R, Macias WL, et al.: Site-directed mutagenesis of predicted active site residues in glutamate carboxypeptidase II. Mol Pharmacol 1999; 55: 179-185. (Pubitemid 29042536)
143. Murphy GP, Elgamal AA, Su SL, et al.: Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998; 83: 2259-2269. (Pubitemid 28533495)
144. Friedrich SW, Lin SC, Stoll BR, et al.: Antibody-directed effector cell therapy of tumors: Analysis and optimization using a physiologically based pharmacokinetic model. Neoplasia 2002; 4: 449-463. (Pubitemid 34976961)
145. Jain RK,: Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990; 50: 814s-819s.
146. Scher B, Seitz M, Albinger W, et al.: Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 2007; 34: 45-53. (Pubitemid 44885553)
147. Rinnab L, Mottaghy FM, Blumstein NM, et al.: Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 2007; 100: 786-793. (Pubitemid 47360183)
148. Reske SN, Blumstein NM, Neumaier B, et al.: Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 2006; 47: 1249-1254. (Pubitemid 47544875)
149. Zophel K, Kotzerke J,: Is 11C-choline the most appropriate tracer for prostate cancer? Against. Eur J Nucl Med Mol Imaging 2004; 31: 756-759. (Pubitemid 38647917)
150. 18F-choline and/or 11C-acetate positron emission tomography: Detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int 2007; 99: 1415-1420. (Pubitemid 47164795)
151. Maresca KP, Hillier SM, Femia FJ, et al.: A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem 2009; 52: 347-357.
152. Hillier SM, Maresca KP, Femia FJ, et al.: Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res 2009; 69: 6932-6940.